Berkeley, United States
Sampling Human is a biotechnology startup with a mission to revolutionize health-related decisions by enabling single cell analysis at a massive scale. Founded in 2016 and headquartered in the United States, the company aims to address the current limitations in clinical diagnosis, which often result in delayed identification and misdiagnosis of rare diseases, impacting patient outcomes.
The startup's focus on Big Data, Biotechnology, and Health Care aligns with the growing need for precise knowledge of physiological units in the human body. Sampling Human aims to overcome the reliance on imprecise symptoms-based medicine by leveraging advanced technology to analyze individual cells, thereby enabling more accurate and timely diagnoses.
Sampling Human recently secured a significant $2.00M investment in a Seed Round on 12 April 2022, with backing from prominent investors including Formic Ventures, i&I Bio, and LongevityTech.fund. This investment underscores the confidence of the investor community in the potential of Sampling Human's innovative approach to transforming healthcare through single cell analysis.
